Introduction {#S1}
============

Despite recent advances in the field of transplantation, recipients of allogeneic hematopoietic stem cell transplantation (HSCT) remain profoundly immunocompromised and at high risk of early death from both infectious and non-infectious complications ([@B1]). Successful engraftment and immune reconstitution of the innate and adaptive immune systems have been associated with lower rates of infection, lower relapse rates, and improved survival ([@B2]). There is high clinical interest in finding appropriate immune biomarkers to predict clinical outcomes associated with immunosuppression in order to individualize clinical care ([@B3]--[@B6]). Following HSCT, clinicians often need to balance the risk of acute graft versus host disease (AGVHD) against infection, with both complications contributing significantly to transplant-related mortality. Potential candidate biomarkers used to predict mortality or AGVHD outcomes include levels of inflammatory cytokines ([@B5]), T-cell subset number (CD4+ or CD8+ T-cells) or rate of recovery ([@B7], [@B8]), C-reactive protein ([@B9]), interleukin receptors ([@B3]), ferritin ([@B10]), and functional immune assays ([@B11]).

We and other investigators have assessed the clinical utility of cytomegalovirus (CMV)-specific T-cell responses in recipients of HSCT in order to identify or predict CMV-related complications ([@B12]--[@B14]). The Quantiferon^®^-CMV is a simple *in vitro* interferon-gamma (IFN-γ) releasing functional assay, which measures whole blood T-cell activity against CMV antigens or phytohemagglutinin (PHA) without the need for peripheral blood mononuclear cell isolation ([@B15]). Here, we aimed to determine the clinical utility of measuring IFN-γ response to the positive mitogen control PHA, not CMV peptides. Previous studies in both solid and stem cell transplant recipients report that the Quantiferon assay is frequently "indeterminate" due to poor mitogen response as a result of immunosuppression ([@B12], [@B16]). Up to 38% of study samples were observed to have low T-cell IFN-γ cytokine function, particularly early posttransplantation when immunosuppression is greatest ([@B12], [@B16]). Because IFN-γ can be measured as a continuous variable, here, we evaluated T-cell responses to PHA in the Quantiferon-CMV assay as a continuous variable and assessed its relationship to clinical outcome in a prospective multicenter cohort study of adult allogeneic HSCT recipients.

Materials and Methods {#S2}
=====================

Study Design {#S2-1}
------------

A prospective observational multicenter study of adult allogeneic HSCT recipients was conducted at two state-wide transplant centers in Melbourne, Australia; the Royal Melbourne Hospital and the Alfred Hospital between January 2011 and May 2014. Inclusion criteria were any participants receiving an allogeneic HSCT and at risk of CMV disease defined as concordant positive recipient (R)/donor (D) serology (R+/D+) or discordant recipient/donor serology (R+/D− and R−/D+) and have previously been reported ([@B13]). For this substudy of mitogen responses, only participants who had available study bloods taken at 3 months were eligible for inclusion. Exclusion criteria included low risk of CMV disease (R−/D−) and presence of CMV disease at the time of transplantation. The study period was 12 months from the date of transplantation and study specific bloods were taken 3, 6, 9, and 12 months post-HSCT. The study was approved by the human research ethics committees of The Alfred (HREC no. 339/10), Melbourne Health (MH 2010.290), and Monash University (CF11/0238-2011000078). Written informed consent was obtained from all participants.

Transplant Protocol {#S2-2}
-------------------

Conditioning regimens for participants undergoing myeloablative HSCT included total body irradiation (day −4 to day −1) and cyclophosphamide of 60 mg/kg/day for 2 days (day −6 to day −5). Participants undergoing reduced intensity conditioning were treated with fludarabine 30 mg/m^2^, day −8 to −4 and melphalan 120--140 mg/m^2^, day −2. Conditioning regimen for T-cell depleted grafts included alemtuzumab or antithymocyte globulin (ATG) day −8 to day −4. Posttransplantation prophylaxis against graft versus host disease (GHVD) was with cyclosporine A plus either methotrexate or mycophenolate mofetil.

Clinical Definitions {#S2-3}
--------------------

Clinical outcomes of interest included AGVHD, chronic graft versus host disease, relapse, non-relapse mortality (NRM), and 12-month overall survival. Diagnosis of AGVHD was defined using the histological biopsy results of the targeted organs involved and graded into categories I-IV according to published international guidelines ([@B17]). The primary cause of death was determined by the treating physician as recorded on the official death certificate.

Immune Monitoring {#S2-4}
-----------------

Immune function was assessed using the commercially available Quantiferon^®^-CMV assay (QIAGEN, Germantown, MD, USA) ([@B15]). This *in vitro* whole blood assay, which quantifies production of IFN-γ following stimulation with (1) human leukocyte antigen (HLA) restricted CMV peptides, (2) PHA as a positive control, and (3) sterile phosphate buffered saline as a negative control. The assay was performed in accordance with manufacturer's instruction as previously described ([@B15], [@B18]). In brief, 1 ml of whole blood is drawn into each of the three tubes and incubated overnight at 37°C. The supernatant was then harvested and ELISA performed for quantification of IFN-γ expressed as International units per milliliter. The final IFN-γ level was calculated by subtracting the IFN-γ expressed in the negative control tube from the PHA tube. The cut-off levels of IFN-γ that indicated a positive response to PHA was defined, as per manufacturer instructions. A low and high mitogen response to PHA was defined as IFN-γ \< 0.5 IU/ml and IFN-γ ≥ 0.5 IU/ml, respectively. The maximum measured level of IFN-γ was 100 IU/ml and responses greater than this level were not accurately quantified.

Statistical Analysis {#S2-5}
--------------------

Comparison of two categorical outcomes were calculated using chi square testing and Fisher's exact test, as appropriate. A Wilcoxon rank sum test or Kruskal--Wallis test were used where groups of non-parametric continuous data were compared. We calculated the change in IFN-γ production in response to PHA over time in each participant using generalized estimating equations (GEE) modeling. Baseline was taken as the production of IFN-γ in response to PHA at 3 months posttransplant, and this model considered both variation at baseline as well as change over time (3--12 months) as an interaction with each group. SEs were calculated using the robust Huber--White sandwich estimator. Kaplan--Meier survival estimates and Cox proportional hazards model were calculated to assess all-cause mortality. Cumulative incidence curves with competing risks analysis were calculated for NRM where relapse was considered a competing event in accordance with statistical guidelines ([@B19]). A *p*-value \<0.05 was considered to be statistically significant. Statistical analyses were performed using Stata 14.1 (Statacorp, College Station, TX, USA: StataCorp LP) and GraphPad Prism (v6; San Diego, CA, USA).

Results {#S3}
=======

Participant Demographics {#S3-1}
------------------------

Ninety-four participants were recruited into the parent study and have been previously described ([@B13]). In brief, the most common indication for HSCT was acute myeloid leukemia (35%) and 63% of all transplants underwent myeloablative conditioning ([@B13]). Seventy-three participants of the parent study met this sub-study's requirement for availability of a 3-month (post-HSCT) sample (see study flow chart Figure [1](#F1){ref-type="fig"}). Basic demographics for the 73 participants included into this sub-study are shown in Table [1](#T1){ref-type="table"}.

![Study participant flow chart. \*Death defined as 12-month all-cause mortality; attributable causes relapse (*n* = 3), infection (*n* = 1). ^\#^Death defined as 12-month all-cause mortality; attributable cause graft versus host disease (*n* = 5), multi-organ failure (*n* = 2), hemorrhage (*n* = 1). AGVHD, acute graft versus host disease.](fimmu-08-01506-g001){#F1}

###### 

Participant characteristics.

                                              Participants   High IFN-γ response to phytohemagglutinin (PHA)   Low IFN-γ response to PHA   Uni-variate   Multi-variate
  ------------------------------------------- -------------- ------------------------------------------------- --------------------------- ------------- ---------------
  Age (years, median IQR)                     50 (40--56)    48.5 (31--56)                                     53 (42--57)                 0.2           --
  Sex (male:female)                           34:39          23:23                                             11:16                       0.4           --
  **Primary diagnosis**                                                                                                                                  
  Acute myeloid leukemia                      25 (34.2)      14 (30.4)                                         11 (40.7)                                 
  Multiple myeloma                            11 (15.1)      10 (21.7)                                         1 (3.7)                                   
  Acute lymphoblastic leukemia                9 (12.3)       5 (10.9)                                          4 (14.8)                                  
  Non-Hodgkins lymphoma                       8 (11)         6 (13)                                            2 (7.4)                                   
  Hodgkins disease                            5 (6.9)        5 (10.9)                                          0                           0.01          0.6
  Myelodysplasia                              5 (6.9)        2 (4.3)                                           3 (11.1)                                  
  Chronic lymphocytic leukemia                4 (5.5)        4 (8.7)                                           0                                         
  Chronic myeloid leukemia                    3 (4.1)        0                                                 3 (11.1)                                  
  Myelofibrosis                               2 (2.8)        0                                                 2 (7.4)                                   
  Blastic plasmacytoid dendritic              1 (1.4)        0                                                 1 (3.7)                                   
  **Type of conditioning**                                                                                                                               
  Myeloablative                               47 (64.4)      26 (56.5)                                         21 (77.8)                   0.07          0.09
  Reduced-intensity conditioning              26 (35.6)      20 (43.5)                                         6 (22.2)                                  
  **Graft source**                                                                                                                                       
  Peripheral blood stem cell                  62 (84.9)      42 (91.3)                                         20 (74.1)                   0.1           --
  Bone marrow                                 4 (5.5)        2 (4.3)                                           2 (7.4)                                   
  Umbilical cord                              7 (9.6)        2 (4.3)                                           5 (18.5)                                  
  **Donor relationship**                                                                                                                                 
  Sibling related                             30 (41.1)      22 (47.8)                                         8 (29.6)                    0.1           --
  Volunteer unrelated donor                   43 (58.9)      24 (52.2)                                         19 (70.4)                                 
  **Conditioning**                                                                                                                                       
  Fludarabine/melphalan                       21 (28.8)      14 (30.4)                                         7 (25.9)                                  
  Cyclophosphamide/TBI                        13 (17.8)      8 (17.4)                                          5 (18.5)                                  
  Busulphan/cyclophosphamide                  10 (13.7)      6 (13)                                            4 (14.8)                                  
  Fludarabine/TBI                             10 (13.7)      10 (21.8)                                         0                           0.05          0.4
  Etoposide/TBI                               5 (6.9)        4 (8.7)                                           1 (3.7)                                   
  Fludarabine/cyclophosphamide                4 (5.5)        2 (4.35)                                          2 (7.4)                                   
  Fludarabine/Cy/TBI/Thiotepa                 4 (5.5)        1 (2.2)                                           3 (11.1)                                  
  Fludarabine/cyclophosphamide/TBI            3 (4.1)        1 (2.2)                                           2 (7.4)                                   
  Other                                       3 (4.1)        0                                                 3 (11.1)                                  
  **HLA match**                                                                                                                                          
  Match                                       54 (74)        38 (82.6)                                         16 (59.3)                   0.03          0.06
  Minor mismatch                              19 (26)        8 (17.4)                                          11 (40.7)                                 
  **Graft versus host disease prophylaxis**                                                                                                              
  Cyclosporin/methotrexate                    46 (63)        29 (63)                                           17 (63)                     0.5           --
  Cyclosporin/mycophenolate                   17 (23.3)      12 (26.1)                                         5 (18.5)                                  
  Cyclosporin                                 8 (11)         4 (8.7)                                           4 (14.8)                                  
  Other                                       2 (2.7)        1 (2.2)                                           1 (3.7)                                   
  ***In vivo* T cell depletion**                                                                                                                         
  Alemtuzumab                                 8 (11)         4 (8.7)                                           4 (14.8)                    0.4           --
  No Alemtuzumab                              65 (89)        42 (91.3)                                         23 (85.2)                                 
  ***In vivo* T cell depletion**                                                                                                                         
  Antithymocyte globulin (ATG)                21 (28.8)      12 (26.1)                                         9 (33.3)                    0.5           --
  No ATG                                      52 (71.2)      34 (73.9)                                         18 (66.7)                                 
  **Baseline cytomegalovirus category**                                                                                                                  
  Recipient+/donor+ (R+/D+)                   33 (45.2)      23 (50)                                           10 (37)                     0.3           --
  Recipient+/donor                            27 (37)        14 (30.4)                                         13 (48.1)                                 
  Recipient                                   13 (17.8)      9 (19.6)                                          4 (14.8)                                  

*IFN-γ, interferon gamma; IQR, interquartile range; TBI, total body irradiation; Cy, cyclophosphamide; HLA, human leukocyte antigen*.

Mitogen Responses Post-HSCT {#S3-2}
---------------------------

Samples were available for evaluation at 207 study time-points; 3 months (*n* = 73), 6 months (*n* = 46), 9 months (*n* = 43), and 12 months (*n* = 45). Each participant contributed a median of 3 (range 1--4) study bloods. The median IFN-γ level following stimulation with PHA for study participants at 3, 6, 9, and 12 months were 2.05, 7.72, 30.5, and 16.63 IU/ml, respectively.

At 3 months post-HSCT, high mitogen responses were seen in 46 (63%) of participants and low mitogen responses were seen in 27 (37%) of participants (Table [1](#T1){ref-type="table"}). The median \[interquartile range (IQR)\] mitogen IFN-γ level in high and low mitogen responders was 7.68 (2.43--33.83) IU/ml and 0.06 (0.01--0.17) IU/ml, respectively. In univariate analysis, the pretransplant factors associated with mitogen response at 3 months were the primary diagnosis (*p* = 0.01) and HLA matching (*p* = 0.03; Table [1](#T1){ref-type="table"}). There was a trend toward significance with the conditioning regimen (*p* = 0.05) and intensity of conditioning (myeloablative versus. reduced intensity; *p* = 0.07). No associations were seen between mitogen responses at 3 months and age (*p* = 0.2), use of an unrelated donor graft (*p* = 0.1), nor T-cell depleting transplants using either alemtuzumab or ATG (*p* = 0.4 and *p* = 0.5, respectively). In a multivariate analysis, adjusted for the primary diagnosis, conditioning regimen, HLA matching, and intensity of conditioning, there was a trend toward HLA matching being an independent determinant of mitogen response at 3 months (*p* = 0.06; Table [1](#T1){ref-type="table"}).

Interferon-gamma response to PHA significantly correlated to peripheral blood lymphocyte count at the time of study sampling (spearman *r* = 0.52, *p* \< 0.001), but not to total white cell count or peripheral blood neutrophil count (Table [2](#T2){ref-type="table"}). The median blood lymphocyte count in high and low mitogen responders at 3 months was 1 \[0.7 − 1.7\] × 10^9^/l and 0.6 \[0.3 − 0.8\] × 10^9^/l, respectively, *p* = 0.0001.

###### 

Transplant-related outcomes.

                                                All participants   High IFN-γ response to mitogen   Low IFN-γ response to mitogen   *p-*Value
  --------------------------------------------- ------------------ -------------------------------- ------------------------------- -----------
  **Blood parameters**                                                                                                              
  Total white cell count (10^9^/l) median IQR   4.4 (3.2--6.4)     4.6 (3.6--6.3)                   4.4 (3--6.7)                    0.6
  Neutrophil count (10^9^/l) median IQR         2.8 (1.8--4.3)     2.7 (1.9--3.7)                   3 (1.7--5.6)                    0.3
  Lymphocyte count (10^9^/l) median, IQR        0.8 (0.5--1.3)     1 (0.7--1.7)                     0.6 (0.3--0.8)                  0.0001
  **Acute GVHD**                                                                                                                    
  Nil                                           35 (48)            25 (54.3)                        10 (37)                         0.001
  Grade I                                       16 (21.9)          12 (26.1)                        4 (14.8)                        
  Grade II                                      12 (16.4)          9 (19.6)                         3 (11.1)                        
  Grade III                                     7 (9.6)            0                                7 (25.9)                        
  Grade IV                                      3 (4.1)            0                                3 (11.1)                        
  **Acute GVHD treatment (*n* = 38)**                                                                                               
  Topical PNL only                              9 (23.7)           8 (38.1)                         1 (5.9)                         0.04
  PNL/cyclosporine or tacrolimus                28 (73.7)          13 (61.9)                        15 (88.2)                       
  PNL/ATG/etanercept/pentostatin                1 (2.7)            0                                1 (5.9)                         
  **Chronic GVHD**                                                                                                                  
  Nil                                           27 (38.6)          17 (37)                          10 (41.7)                       0.9
  Limited                                       16 (22.9)          11 (23.9)                        5 (20.8)                        
  Extensive                                     27 (38.6)          18 (39.1)                        9 (37.5)                        
  **Death at 12 months**                                                                                                            
  All-cause mortality                           12 (16.4)          4 (8.7)                          8 (29.6)                        0.046
  **Attributable death at 12 months**                                                                                               
  Graft versus host disease                     5 (6.8)            0                                5 (18.5)                        
  Relapse/progressive disease                   3 (4.1)            3 (6.5)                          0                               
  Multiorgan failure                            2 (2.7)            0                                2 (7.4)                         
  Hemorrhage                                    1 (1.4)            0                                1 (3.7)                         
  Infection                                     1 (1.4)            1 (2.2)                          0                               

*PNL, prednisolone; ATG, antithymocyte globulin; GVHD, graft-versus-host-disease; IQR, interquartile range*.

We compared the longitudinal measurement of IFN-γ response to PHA between high and low mitogen responders (measured at 3 months post HSCT) over the study period (Figure [2](#F2){ref-type="fig"}). In high mitogen responders, the rate of IFN-γ response to PHA between 3 and 12 months post-HSCT did not change significantly (GEE estimated coefficient 0.02 *p* = 0.2; Figure [2](#F2){ref-type="fig"}A). In low mitogen responders, there was a significant increase in the IFN-γ response to PHA between 3 and 12 months (GEE estimated coefficient 0.23 *p* \< 0.0001; Figure [2](#F2){ref-type="fig"}B).

![Production of interferon-gamma (IFN-γ) in response to phytohemagglutinin was measured from 3 to 12 months following hematopoietic stem cell transplantation (HSCT) in recipients with **(A)**. High mitogen responses (≥0.5 IFN-γ IU/ml) measured at 3 months post-HSCT and **(B)**. Low mitogen responses (\<0.5 IFN-γ IU/ml) measured at 3 months.](fimmu-08-01506-g002){#F2}

PHA Responses Predict Survival Outcomes {#S3-3}
---------------------------------------

Twelve of the 73 study participants did not survive to 12 months (16.4%) with the attributable cause of death being AGVHD (*n* = 5), relapse of primary disease (*n* = 3), multi-organ failure (*n* = 2), hemorrhage (*n* = 1), and infection (*n* = 1), see Table [2](#T2){ref-type="table"}. The overall 12-month survival significantly differed between individuals with a high versus low IFN-γ response to PHA at 3 months (92 vs. 62%, respectively, Mantel-Cox log-rank test *p* = 0.01; Figure [3](#F3){ref-type="fig"}A). The risk of death at any time in participants with a low vs. high response to PHA was significantly increased \[Cox proportional hazards ratio (HR): 4.12 95% CI: 1.2--13.7, *p* = 0.02, Figure [3](#F3){ref-type="fig"}A\]. After adjusting for the presence of AGVHD, the Cox proportional HR was 3.3 95% CI: 1--11, *p* = 0.052.

![Survival and mortality in hematopoietic stem cell transplantation (HSCT) study participants stratified by low and high interferon-gamma production following phytohemagglutinin stimulation measured 3 months following HSCT. **(A)** Kaplan--Meier overall survival estimates and **(B)** cumulative incidence curve for non-relapse mortality are shown.](fimmu-08-01506-g003){#F3}

The cumulative incidence curve for NRM according to IFN-γ response to PHA is shown in Figure [3](#F3){ref-type="fig"}B. Participants with a low compared to high IFN-γ response to PHA at 3 months had a significantly increased risk of NRM at 12 months (competing risk analysis hazards ratio HR: 11.6 95% CI: 1.4--94.5, *p* = 0.02).

PHA Responses Predict Survival in Individuals with AGVHD {#S3-4}
--------------------------------------------------------

All study deaths (*n* = 12) occurred in HSCT recipients who developed AGVHD where AGVHD was either a direct (*n* = 5) or an indirect contributor to death (*n* = 7). AGVHD occurred in 38 of 73 (52%) participants at a median of 40 days (IQR 29--62) post HSCT. The development of AGVHD was not associated with IFN-γ response to PHA at 3 months (*p* = 0.15). There was no difference in the IFN-response to PHA at 3 months between those who did and did not develop AGVHD (median IFN-γ 1.47 vs. 2.34 IU/ml, respectively, *p* = 0.2 Figure [4](#F4){ref-type="fig"}A). However, the severity of AGHVD was strongly associated with IFN-γ response to PHA where all participants with grade III-IV AGVHD had low IFN-γ response to PHA (*p* = 0.001; Table [2](#T2){ref-type="table"}). The treatment received for AGVHD was associated with IFN-γ response to PHA at 3 months. Participants receiving topical prednisolone for lower grade AGVHD (grade I-II) were more likely to have high IFN-γ response to PHA at 3 months (*p* = 0.04, Table [2](#T2){ref-type="table"}). There was no significant difference in the time of onset of AGVHD between participants who had high and low IFN-γ response to PHA at 3 months (42 vs. 36 days, *p* = 0.2). Development of chronic GVHD was not associated with the IFN-γ response to PHA at 3 months post-HSCT (*p* = 0.9).

![IFN-γ responses to phytohemagglutinin (PHA) and survival in individuals with and without acute graft versus host disease (AGVHD) following hematopoietic stem cell transplantation. **(A)** Comparison of the IFN-γ response (International units per milliliter) to PHA in participants with and without AGVHD at 3 months. The dotted horizontal line at an interferon-gamma (IFN-γ) level of 0.5 IU/ml represents the cut-off value determining high and low responses, according to the assay manufacturer. **(B)** Kaplan--Meier overall survival estimates for participants with and without AGVHD and **(C)** stratified by high and low IFN-γ response to PHA.](fimmu-08-01506-g004){#F4}

In participants who did not develop AGVHD, a low IFN-γ response to PHA at 3 months was observed in 28.6% of individuals (Figure [1](#F1){ref-type="fig"}). No patient deaths occurred in this group. There were no associations seen between IFN-γ response to PHA and T-cell depleting grafts using alemtuzumab or ATG in participants without AGVHD (Fisher's exact *p* = 0.3).

Individuals with AGVHD compared to no AGVHD had reduced 12-month overall survival (68 vs 100%, respectively, Mantel log-rank test *p* \< 0.0003; Figure [4](#F4){ref-type="fig"}B). The inclusion of IFN-γ response to PHA at 3 months post-HSCT in participants with AGVHD was able to predict and risk stratify participants with reduced 12-month overall survival. Survival rates in participants with no AGVHD compared to AGVHD with high IFN-γ response to PHA compared to AGVHD with low IFN-γ response to PHA was 100 vs. 80 vs. 52%, respectively (log-rank test *p* \< 0.0001; Figure [4](#F4){ref-type="fig"}C). Of the 38 participants who developed AGVHD, the IFN-γ response to PHA at 3 months had 89% sensitivity and 69% specificity for NRM. The positive predictive value of developing NRM based on IFN-γ response to PHA at 3 months was 47% with a negative predictive value of 95%.

Discussion {#S4}
==========

In this study, we prospectively evaluated IFN-γ production in response to PHA using a rapid and simple IFN-γ release assay and found that low IFN-γ response to PHA measured 3 months post-HSCT was predictive of lower 12-month survival and increased NRM. AGVHD severity was highly associated with IFN-γ response to PHA, and this relationship likely reflects the immunosuppressive effects of AGVHD and/or its treatment. Among HSCT recipients with AGVHD, the IFN-γ response to PHA also predicted 12-month survival. A low IFN-γ response to PHA could allow individualized tailoring of immunosuppression to potentially prevent poor transplant-related outcomes.

A biomarker that could accurately assess an individual's level of immunosuppression is of high clinical interest ([@B20], [@B21]). Potential biomarkers should ideally be easy to perform, be reproducible, and accurately predict outcomes such as AGVHD ([@B3], [@B5]), infection ([@B9], [@B22]), and survival ([@B3], [@B9]). Candidate biomarker targets have included T-cell subsets ([@B7], [@B23]), functional immune assays ([@B11], [@B23]), inflammatory cytokines ([@B22]), and interleukin receptors ([@B5]). T-cell subset numbers, particularly higher CD8+ T-cells but not CD4+ T-cells, at day 90 were recently observed to predict enhanced survival in a cohort of HSCT recipients but immune function was not assessed ([@B7]). The Cylex ImmuKnow^®^ is another immune monitoring assay, which after stimulation with PHA measures intracellular adenosine triphosphate levels in CD4+ T-cells ([@B24]). Several studies in the HSCT population did not demonstrate any additional clinical value of the ImmunKnow assay ([@B11], [@B25], [@B26]). More complex biomarkers such as T-cell immunoglobulin and mucin-domain containing 3 (TIM3), interleukin-6, soluble tumor necrosis factor receptor 1, and plasma suppression of tumorigenicity 2 have shown some promise in predicting AGVHD and NRM ([@B3], [@B5]).

Both the Quantiferon-CMV and Quantiferon-TB (tuberculosis) assay include a PHA control and, therefore, both assays could potentially be used to risk stratify individuals at high risk of poor survival. Advantages of the Quantiferon assay are that it is simple to perform in a routine diagnostic laboratory, is standardized, and results could be available in real time to help guide clinical decisions. These assay characteristics address some of the concerns that candidate biomarker assays are too complicated or technically sophisticated to be used in clinical practice ([@B20]). Here, we showed the assay had some predictive value which could potentially impact on clinical decision-making. A major limitation in assessing individual biomarkers has been the clinical interpretation, since statistically significant differences do not necessarily translate into changes in clinical management or diagnostic accuracy ([@B20]).

There are several limitations to this study. The overall size of the cohort was relatively small and the study results need further validation in a larger cohort. We assessed clinical outcomes at 12 months post-HSCT, but a longer duration of follow-up should be examined to determine durable clinical benefits. As we only assessed a single cytokine IFN-γ using whole blood, the exact cellular source of IFN-γ was not evaluated and could have been from either T-cells or natural killer cells. Furthermore, the assay evaluated in this study did not assess the quantity or phenotype of the T-cell response.

In conclusion, low IFN-γ responses to PHA stimulation measured 3 months following allogeneic HSCT was predictive of increased NRM and reduced 12-month overall survival, particularly in recipients who developed AGVHD. This IFN-γ release assay is a simple and easy to perform assay with the capacity for high throughput. Further validation of the clinical utility of this assay in a larger HSCT cohort is warranted.
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